ArticleThe journal of nutrition, health & aging2025
Cardiovascular-kidney-metabolic overlaps, clinical outcomes, and quality of life in patients with acute heart failure.
Article in The journal of nutrition, health & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Joint association of high-sensitivity C-reactive protein and cumulative atherogenic index of plasma with cardiovascular disease risk in CKM syndrome stages 0-3: a prospective cohort study.BMC cardiovascular disorders · 2026Article
- Unraveling the Cardiorenal Nexus - Emerging Frameworks and the Role of Exercise Therapy.Circulation reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of cardiovascular-kidney-metabolic (CKM) multimorbidity on outcomes in heart failure (HF) patients from China is not well-characterized.
objectivesTo evaluate the influence of CKM multimorbidity on short-term and long-term clinical outcomes and health-related quality of life.
methodsUsing data from a multicenter prospective cohort in China, we classified patients hospitalized for HF according to numbers or combinations of CKM conditions (atherosclerotic cardiovascular disease [ASCVD]), chronic kidney disease [CKD], and type 2 diabetes [T2D]). Cox regression models assessed associations of CKM multimorbidity with 1-year major adverse cardiovascular events (MACE), all-cause death, cardiovascular (CV) death, all-cause rehospitalization, HF rehospitalization, and 4-year mortality outcomes. Generalized linear models evaluated CKM multimorbidity's impact on 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) scores at 1, 6, and 12 months post-discharge.
resultsAmong 4875 patients, 68.2% had at least one CKM condition, and 8.0% had all three. Having three CKM conditions significantly increased 1-year MACE (adjusted hazard ratio [aHR] 1.87), all-cause death (aHR 1.78), CV death (aHR 1.78), all-cause rehospitalization (aHR 1.70), HF rehospitalization (aHR 1.76), 4-year all-cause death (aHR 1.95), and CV death (aHR 1.78). Patients with three CKM conditions had a 12-month KCCQ-12 score difference of -6.35 compared to those with no CKM conditions.
conclusionsCKM multimorbidity is common in Chinese patients hospitalized for HF and is associated with a higher risk of clinical outcomes and lower health-related quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.